PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 29, 2026Journal of Nuclear Medicine0 citations

Improving Somatostatin Receptor Assessment Using 99mTc-Radiolabeled Antagonist in Neuroendocrine...

Improving the Somatostatin Receptor Status Assessment for Personalized and Precise Management of Neuroendocrine Neoplasms with the Use of a 99m Tc-Radiolabeled Somatostatin Receptor Antagonist: The Final Results of the ERA PerMed TECANT Clinical Trial

View Full Paper

Authors

AHAlicja Hubalewska-DydejczykCDClemens DecristoforoRMRenata Mikolajczak

Discussion

Loading...

Member takes

Overview

Clinical trial demonstrates improved imaging for neuroendocrine neoplasms, suggesting enhanced diagnostic options.

Key Points

  • This study aims to assess the safety and performance of a novel 99mTc-labeled somatostatin receptor antagonist in patients with neuroendocrine neoplasms.
  • Conducted a first-in-human injection of [99mTc]Tc-TECANT1 in ten patients with metastatic grade 1 or 2 neuroendocrine neoplasms.
  • Evaluated safety, pharmacokinetics, and dosimetry as primary endpoints.
  • Performed qualitative and quantitative comparison with 68Ga-SSTR PET for secondary endpoints.
  • [99mTc]Tc-TECANT1 was safe with a total body effective dose of 3.3 ± 0.7 mSv.
  • Superior diagnostic performance compared to SSTR PET was observed, with more detected lesions.
  • Achieved target-to-background contrast exceeding a factor of 2 for high-uptake lesions.
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hubalewska-Dydejczyk et al. (2026) studied this question.

synapsesocial.com/papers/69c8c115de0f0f753b39ba79https://doi.org/10.2967/jnumed.125.270347
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1How close we are to optimise the assessment of SSTR status in NEN with a radiolabelled SSTR antagonist-final results of the TECANT clinical trial: Novel 99mTc-labelled somatostatin antagonists in the diagnostic algorithm of neuroendocrine neoplasms2024
  2. 2Controversies in <scp>NEN</scp> : An <scp>ENETS</scp> position statement on the interchangeability of somatostatin receptor <scp>PET</scp> tracers2026
  3. 3Targeted radionuclide therapy and diagnostic imaging of SSTR positive neuroendocrine tumors: a clinical update in the new decade2025 · 8 citations
  4. 4Machine Learning Uncovers Novel Predictors of Peptide Receptor Radionuclide Therapy Eligibility in Neuroendocrine Neoplasms2025
  5. 5Machine Learning Uncovers Novel Predictors of PRRT Eligibility in Neuroendocrine Neoplasms2025